These mutations suggest that disruption in the PI3K pathway, TP53 pathway, and chromatin modification mediated gene expression driven by ASXL1 are driving the tumorigenesis in this tumor (Supplementary Table 1). The gene discussed is ASXL1; the disease is neoplasm.